Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zoetis (NY:ZTS)

147.10 +0.17 (+0.12%)
Streaming Delayed Price Updated: 1:23 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zoetis

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Here's How Much $100 Invested In Zoetis 10 Years Ago Would Be Worth Today
 
Via Benzinga
Zoetis Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
 
Via Benzinga
How Do Investors Really Feel About Zoetis?
 
Via Benzinga
Zoetis Beats Wall Street Estimates, Revises 2025 Guidance To Include Tariffs Impact
Zoetis beats Q1 estimates with $1.48 EPS and $2.22 billion revenue, raises full-year forecast on strong demand for companion animal health products. 
Via Benzinga
Which S&P500 stocks are gapping on Tuesday?
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Tuesday to find the gap up and gap down stocks in today's session. 
Via Chartmill
Earnings Scheduled For May 6, 2025
 
Via Benzinga
P/E Ratio Insights for Zoetis
 
Via Benzinga
Looking Into Zoetis's Recent Short Interest
 
Via Benzinga
Stocks Fall On Trade Concerns, Oil And Gold Rally: What's Driving Markets Tuesday?
Wall Street edged lower by midday Tuesday as uncertainty surrounding trade policies lingered, with investors adopting a cautious approach ahead of Wednesday’s Federal Reserve meeting. 
Via Benzinga
Topics Economy
Zoetis’s (NYSE:ZTS) Q1: Beats On Revenue, Full-Year Sales Guidance is Optimistic
Animal health company Zoetis (NYSE:ZTS) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 1.4% year on year to $2.22 billion. The company’s full-year revenue guidance... 
Via StockStory
Zoetis Announces First Quarter 2025 Results
From Zoetis Inc.
Via Business Wire
Zoetis (ZTS) Q1 Earnings: What To Expect
Animal health company Zoetis (NYSE:ZTS) will be announcing earnings results tomorrow before market hours. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
1 Safe-and-Steady Stock to Target This Week and 2 to Be Wary Of
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
Via The Motley Fool
Topics Economy Intellectual Property World Trade
1 Superstar Dividend Growth Stock to Buy if the Market Crashes
Investors have been waiting nearly a decade to score a good deal on this healthcare star. 
Via The Motley Fool
Topics Economy Government
A Once-in-a-Decade Opportunity: 3 Magnificent Stocks Down Between 40% and 73% to Buy Right Now
Via The Motley Fool
3 Magnificent Stocks to Buy That Are Near 52-Week Lows
Via The Motley Fool
Topics Economy Government
2 of Wall Street’s Favorite Stocks with Competitive Advantages and 1 to Be Wary Of
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
This Magnificent Dividend Stock Has Increased Its Payouts by 500% in 10 Years
Via The Motley Fool
A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Zoetis' Stock Is About as Cheap as It's Ever Been. 1 Thing to Know Before You Buy.
Via The Motley Fool
Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results
From Zoetis Inc.
Via Business Wire
Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Stop Chasing Returns And Start Getting Rising Dividends With These 10 Blue Chip Stocks
Instead of chasing returns, investors can start building long-term passive income through dividend growth stocks. 
Via Talk Markets
Topics Stocks / Equities
Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX)... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how pharmaceuticals stocks fared in Q4, starting with Elanco... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ:CORT) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.